EMA panel backs EU approval of Roche’s Ocrevus for pediatric relapsing MS patients 10+
Bitget2026/09/18 10:45- EMA’s CHMP recommended EU approval of Roche’s Ocrevus IV for relapsing multiple sclerosis in patients aged 10 and older.
- European Commission decision expected soon; FDA cleared the pediatric use in May 2026.
- Phase III OPERETTA 2 showed non-inferior relapse control versus fingolimod; 48% lower relapse risk.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Stonex sets initial price target for NXP at $340
Wells Fargo (WFC.US) doubles its IBIT holdings for clients as U.S. institutions significantly increase positions in Q3
According to the 13F report, Wells Fargo's client holdings of IBIT shares have doubled to nearly 50 million shares, equivalent to 30,553 BTC. Institutions such as Goldman Sachs and Bank of America have also significantly increased their holdings of spot bitcoin ETFs. Despite the current bitcoin price falling more than 20% from the quarter-end, institutional enthusiasm for allocation remains strong.

Musk: China is a super fan, Tesla will increase production

Australian job market suddenly stalls! Unemployment rate hits a five-year high, traders move forward Reserve Bank rate cut bets to September next year
Australia's soaring unemployment rate has prompted traders to price in interest rate cuts.
